title: Randomised Phase III study of biweekly 24-h infusion of high-dose 5FU with folinic acid and oxaliplatin versus monthly plus 5-FU/folinic acid in first-line treatment of advanced colorectal cancer.
abstract: BACKGROUND
  A phase III study was started to compare oxaliplatin/5FU/LV in the first-line with bolus FU/LV in metastatic colorectal cancer.
  
  
  METHODS
  302 patients were randomised and received bolus 5-FU 425 mg/m(2) day 1-5, FA 20 mg/m(2) day 1-5, q 4 wk or oxaliplatin 85 mg/m(2), 2 h-infusion, FA 200 mg/m(2), 1-h infusion. 5-FU 2600 mg/m(2), 24-h infusion day 1, q 2 wk. The primary endpoint was response rate (RR).
  
  
  RESULTS
  The median follow-up is 31.8 months, 90.4% of the patients have died. Confirmed RR, progression free survival (PFS; months) and median overall survival (OS; months) in 5FU/LV versus 5FU/LV/oxaliplatin were respectively 18.5% versus (vs) 33.8% (P = 0.004), 5.6 vs 6.7 (P = 0.016) and 13.3 vs 13.8 (P = 0.619). In the 5FU/LV/oxaliplatin arm less grade (3/4) toxicity was measured for diarrhoea, stomatitis, an increase in idiosyncratic side effects and neurosensory events compared with 5FU/LV. The quality of life (QOL) was equal in both arms. Second line treatment was given in 62% of the patients, crossover of 5FU/LV to 5FU/LV/oxaliplatin occurred in 14%.
  
  
  CONCLUSIONS
  Oxaliplatin in the first-line resulted in an increased RR and PFS with less grade 3/4 mucositis/diarrhoea compared with 5FU/LV alone. Idiosyncratic side effects deserve attention with oxaliplatin. Despite a low treatment cross over rate, OS in both groups was comparable.
authors.affiliation: Department of Medical Oncology, University of Groningen and University Medical Center Groningen, Groningen, The Netherlands. g.a.p.hospers@int.umcg.nl
authors.forename: G A P
authors.initials: GA
authors.lastname: Hospers
authors.forename: M
authors.initials: M
authors.lastname: Schaapveld
authors.forename: J W R
authors.initials: JW
authors.lastname: Nortier
authors.forename: J
authors.initials: J
authors.lastname: Wils
authors.forename: A
authors.initials: A
authors.lastname: van Bochove
authors.forename: R S
authors.initials: RS
authors.lastname: de Jong
authors.forename: G J
authors.initials: GJ
authors.lastname: Creemers
authors.forename: Z
authors.initials: Z
authors.lastname: Erjavec
authors.forename: D J
authors.initials: DJ
authors.lastname: de Gooyer
authors.forename: P H Th J
authors.initials: PH
authors.lastname: Slee
authors.forename: C J H
authors.initials: CJ
authors.lastname: Gerrits
authors.forename: J M
authors.initials: JM
authors.lastname: Smit
authors.forename: N H
authors.initials: NH
authors.lastname: Mulder
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D000077150:Oxaliplatin; D011788:Quality of Life; D016879:Salvage Therapy
chemical_list: D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D002955:Leucovorin; D005472:Fluorouracil